Patients with XLPP have C-terminal truncating pathogenic variants in the last exon of 5-aminolevulinic acid synthase 2 (ALAS2), the first and rate-limiting step in erythroid heme synthesis. The gene discussed is ALAS2; the disease is X-linked erythropoietic protoporphyria.